NDA 209299 · Rigel Pharms
Tavalisse
Fostamatinib Disodium · Oral
NovelOrphanLast checked: Nov 20, 2026Latest source record: Feb 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Apr 17, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
25
10 Phase 3, 0 recruiting
FAERS reports
7,889
2,613 serious, 493 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2025.
TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Mechanism: Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). The major metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- TAVALISSE · FOSTAMATINIB DISODIUM EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
- TAVALISSE · FOSTAMATINIB DISODIUM EQ 150MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fostamatinib Disodium" as an intervention, any sponsor and status, largest first.
- Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)Pivotal-lookingTerminated
AstraZenecaAstraZeneca (AZN)
NCT01242514 · 1,917 participants · Start Jan 2011 · Primary completion Jan 2015
Drug: Fostamatinib; Fostamatinib and 1 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 308 sites in all
- Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01197521 · 923 participants · Start Sep 2010 · Primary completion Nov 2012
Drug: fostamatinib; fostamatinib and 1 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 127 sites in all
- Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01197534 · 913 participants · Start Sep 2010 · Primary completion Mar 2013
Drug: fostamatinib; fostamatinib and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 149 sites in all
- Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)Pivotal-lookingTerminated
AstraZenecaAstraZeneca (AZN)
NCT01264770 · 644 participants · Start Jan 2011 · Primary completion Oct 2012
Drug: Fostamatinib and placebo injections; Fostamatinib and placebo injections and 3 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 105 sites in all
AstraZenecaAstraZeneca (AZN)
NCT00805467 · 624 participants · Start Aug 2008 · Primary completion Aug 2013
Drug: Fostamatinib Disodium (R935788) · For: Rheumatoid Arthritis
Sites: La Jolla, California; Palm Desert, California; Palo Alto, California · 76 sites in all
- Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid ArthritisPivotal-lookingCompleted
Rigel PharmaceuticalsIndustry
NCT00665925 · 457 participants · Start May 2008 · Primary completion Jun 2009
Drug: Fostamatinib disodium (R935788); Fostamatinib disodium (R935788) and 1 more · For: Rheumatoid Arthritis
Sites: La Jolla, California; Palm Desert, California; Hamden, Connecticut · 65 sites in all
AstraZenecaAstraZeneca (AZN)
NCT01197755 · 323 participants · Start Sep 2010 · Primary completion Feb 2013
Drug: fostamatinib; fostamatinib and 1 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 135 sites in all
- Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 SubjectsPivotal-lookingCompleted
Rigel PharmaceuticalsIndustry
NCT04629703 · 280 participants · Start Mar 25, 2021 · Primary completion Sep 5, 2022
Drug: Fostamatinib; Placebo · For: Covid19; SARS (Severe Acute Respiratory Syndrome); SARS Pneumonia and 3 more
Sites: Orange, California; Washington D.C., District of Columbia; Hialeah, Florida · 47 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,068
- product dose omission issue1,026
- platelet count decreased1,019
- off label use873
- hospitalisation508
- platelet count498
- drug ineffective433
- fatigue403
- blood pressure increased384
- death342
- product prescribing issue316
- headache273
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 155 |
| 2019 | 619 |
| 2020 | 650 |
| 2021 | 454 |
| 2022 | 773 |
| 2023 | 1,119 |
| 2024 | 1,302 |
| 2025 | 1,325 |
| 2026 | 1,490 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tavalisse (Fostamatinib Disodium)
2024 spending
$47.4M
Beneficiaries
562
3,395 claims
Per beneficiary
$84,373
$240.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $21,711,458 |
| 2021 | $25,300,768 |
| 2022 | $32,398,967 |
| 2023 | $39,505,314 |
| 2024 | $47,417,690 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW, Sharman J, Sweetenham J, et al. · Blood 2010 · Clinical Trial, Phase I, Clinical Trial, Phase II
- An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC, Kavanaugh A, Weinblatt ME, et al. · Arthritis Rheum 2011 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Rigel Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.